These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16482567)

  • 1. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
    Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ
    Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
    Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
    Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin in prostate cancer bone metastasis.
    Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
    Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
    Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
    Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-I and MAP kinase involvement in the stimulatory effects of LNCaP prostate cancer cell conditioned media on cell proliferation and protein synthesis in MC3T3-E1 osteoblastic cells.
    Bhattacharyya RS; Stern PH
    J Cell Biochem; 2003 Dec; 90(5):925-37. PubMed ID: 14624452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.
    Koutsilieris M; Reyes-Moreno C; Sourla A; Dimitriadou V; Choki I
    Anticancer Res; 1997; 17(3A):1461-5. PubMed ID: 9179184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
    Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism.
    Schulze J; Albers J; Baranowsky A; Keller J; Spiro A; Streichert T; Zustin J; Amling M; Schinke T
    Bone; 2010 Feb; 46(2):524-33. PubMed ID: 19796718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse.
    Soos G; Jones RF; Haas GP; Wang CY
    Anticancer Res; 1997; 17(6D):4253-8. PubMed ID: 9494517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer.
    Kawada M; Inoue H; Masuda T; Ikeda D
    Cancer Res; 2006 Apr; 66(8):4419-25. PubMed ID: 16618768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vivo model of prostate carcinoma growth and invasion in bone.
    Fisher JL; Schmitt JF; Howard ML; Mackie PS; Choong PF; Risbridger GP
    Cell Tissue Res; 2002 Mar; 307(3):337-45. PubMed ID: 11904770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparanase promotes bone destruction and invasiveness in prostate cancer.
    Zhou Y; Song B; Qin WJ; Zhang G; Zhang R; Luan Q; Pan TJ; Yang AG; Wang H
    Cancer Lett; 2008 Sep; 268(2):252-9. PubMed ID: 18487013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.